Bavarian Nordic AS (CHIX:BAVAC) Receivables Turnover: 1.27 (As of Mar. 2026)


CHIX:BAVAC Bavarian Nordic AS CHIX:BAVAC
82 GF Score
Price kr188.30
GF Value kr166.22
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Bavarian Nordic AS Receivables Turnover?

Bavarian Nordic AS CHIX:BAVAC 82 Receivables Turnover is 1.27 as of Mar. 2026. GuruFocus rates CHIX:BAVAC with a GF Score™ of 82/100 and a GF Value™ of kr166.22 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 840 Biotechnology companies, Bavarian Nordic AS ranks better than 56.67% on this metric.

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bavarian Nordic AS's Revenue for the three months ended in Mar. 2026 was kr1,058 Mil. Bavarian Nordic AS's average Accounts Receivable for the three months ended in Mar. 2026 was kr831 Mil. Hence, Bavarian Nordic AS's Receivables Turnover for the three months ended in Mar. 2026 was 1.27.


Bavarian Nordic AS  (CHIX:BAVAc) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


Bavarian Nordic AS Receivables Turnover Related Terms


Bavarian Nordic AS Receivables Turnover Historical Data

* Premium members only.

The historical data trend for Bavarian Nordic AS's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bavarian Nordic AS Receivables Turnover Chart

Bavarian Nordic AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.29 6.96 6.14 3.87 6.38

Bavarian Nordic AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 1.59 1.68 1.45 1.27

CHIX:BAVAC vs VRTX, REGN, ALNY: Receivables Turnover Comparison

For the Biotechnology subindustry, Bavarian Nordic AS's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bavarian Nordic AS Receivables Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Bavarian Nordic AS's Receivables Turnover falls into.


CHIX:BAVAC
82GF Score
Bavarian Nordic AS CHIX:BAVAC
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bavarian Nordic AS Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Bavarian Nordic AS's Receivables Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Receivables Turnover (A: Dec. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2025 ) / ((Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count )
=6243.956 / ((1175.744 + 780.298) / 2 )
=6243.956 / 978.021
=6.38

Bavarian Nordic AS's Receivables Turnover for the quarter that ended in Mar. 2026 is calculated as

Receivables Turnover (Q: Mar. 2026 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Mar. 2026 ) / ((Accounts Receivable (Q: Dec. 2025 ) + Accounts Receivable (Q: Mar. 2026 )) / count )
=1057.845 / ((780.298 + 881.542) / 2 )
=1057.845 / 830.92
=1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Receivables Turnover →
What does a Receivables Turnover of 1.27 mean?
Bavarian Nordic AS (CHIX:BAVAC) has a Receivables Turnover of 1.27 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bavarian Nordic AS and its competitors. According to the industry distribution chart, Bavarian Nordic AS ranks #364 out of 840 companies in the Biotechnology industry, placing it in the top 43.3%.
Is Bavarian Nordic AS's Receivables Turnover too high?
Bavarian Nordic AS's current Receivables Turnover is 1.27. The Biotechnology industry median Receivables Turnover is 5.30. Bavarian Nordic AS's value of 1.27 is 76% below this industry median. Based on the distribution chart, Bavarian Nordic AS ranks #364 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bavarian Nordic AS has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #364 out of 840 companies for Receivables Turnover. This puts Bavarian Nordic AS in the upper half of its industry. The industry median Receivables Turnover is 5.30. Bavarian Nordic AS's value of 1.27 is 76% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bavarian Nordic AS's current Receivables Turnover of 1.27 is 76% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current Receivables Turnover is 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (CHIX:BAVAC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr166.22, compared to a current price of kr188.30 — trading 13.3% above its estimated fair value. The current Receivables Turnover is 1.27 and 76% below the Biotechnology industry median of 5.30. Bavarian Nordic AS's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Receivables Turnover is 1.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?

Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued. The current stock price of kr188.30 is trading 13.3% above its estimated GF Value™ of kr166.22. GuruFocus considers Bavarian Nordic AS to be Modestly Overvalued.

Key valuation signals for CHIX:BAVAC:

  • Receivables Turnover: 1.27
  • GF Value™: kr166.22 vs. price of kr188.30 (13.3% above fair value)
  • GF Score™: 82/100 with 3 warning signs
  • Industry Position: 76% below the Biotechnology median (#364 of 840)

No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bavarian Nordic AS Business Description

Address Philip Heymans Alle 3, Hellerup, DNK, 2900
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
82GF Score

Get the complete analysis for CHIX:BAVAC

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr188.30
Price
kr166.22
GF Value